Vaccine Research Center Seminar Series, Winter 2012
Vaccine Research Center Seminar Series, Winter 2012:
Jan 24 Jeff Cohen NIAID, NIH - Herpes simplex virus 2 vaccines: Beyond glycoprotein
Jan 31 Chris Walker Ohio State University - Immune control of persistent hepatitis C virus infection
Feb 7 Fred Alt Harvard University - High throughput analysis of mechanisms that influence [...]
Sinovac Begins the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
Sinovac Biotech Ltd.begins the phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. According to the results of phase II clinical trial, the formulation of 400U with aluminum adjuvant was [...]
Promise of Lifetime Flu Vaccine
SEEK, a UK privately-owned drug-discovery group, reports preliminary successful trials of a new vaccine that provides lifetime protection against all influenza strains after single vaccination. The Seek’s press release says that the Universal Flu vaccine could be available for use in the next 3-5 years.
HHS releases new strategic plan to advance vaccine and immunization science and policy for the next decade
The U.S. Department of Health and Human Services today unveiled a new National Vaccine Plan to enhance coordination of all aspects of federal vaccine and immunization activities. Its goal is to ensure that all Americans can access the preventive benefits of vaccines.
The plan is a wide-ranging guide to innovating the nation’s vaccine system. It addresses [...]
BARDA Supports Next Steps for a New Antiviral Drug for Smallpox
A $24.8 million federal contract will support development a new antiviral drug to treat smallpox. The Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, will fund the contract with Chimerix, Inc., of Durham, N.C. The contract can be [...]
DNA Vaccines 2010, March 2 - 4, 2010, New Orleans, LA
DNA Vaccines 2010 will be held March 2 - 4, 2010, at Sheraton New Orleans Hotel, New Orleans, LA. This meeting will follow the same successful pattern as the prior meeting for leading researcher to gather and report on the latest cutting edge research currently being undertaken in the progressive field of DNA or [...]
Leukemia Vaccine Shows Promise
BioSante Pharmaceuticals, Inc. announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). BioSante owns the commercial rights to all GVAX vaccines as a result [...]
Cell-based Viral Vaccines: FDA Issues Final Guidance
To boost development of cell-based viral vaccines FDA issued final guidance. Today’s guidance outlines the best practices using current and emerging science to safely expand the types of cells that may be used to produce vaccines.
According to a recent market study “Global Pandemic Influenza Preparedness Market Forecast 2010-2015“, cell-based development will be the core of [...]
Anthrax Vaccine Contract for $78.4 Awarded by HHS
A biodefense company PharmAthene, Inc., specializing in the development and commercialization of medical countermeasures against chemical and biological threats, has been awarded additional contract for $78.4 by Department of Health and Human Services (HHS) to develop a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National [...]
Pneumococcal Disease Vaccine Approved by FDA
Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years, has been approved by FDA. The new vaccine extends the protection to six additional types of the disease causing bacteria. Prevnar 13 is the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in [...]
